Literature DB >> 32794540

The iboga enigma: the chemistry and neuropharmacology of iboga alkaloids and related analogs.

Rishab N Iyer1, David Favela1, Guoliang Zhang1, David E Olson1,2,3.   

Abstract

Covering: 2000 up to 2020 Few classes of natural products have inspired as many chemists and biologists as have the iboga alkaloids. This family of monoterpenoid indole alkaloids includes the anti-addictive compound ibogaine as well as catharanthine, a precursor to the chemotherapeutic vinblastine. Despite being known for over 120 years, these small molecules continue to challenge our assumptions about biosynthetic pathways, catalyze our creativity for constructing complex architectures, and embolden new approaches for treating mental illness. This review will cover recent advances in both the biosynthesis and chemical synthesis of iboga alkaloids as well as their use as next-generation neurotherapeutics. Whenever appropriate, we provide historical context for the discoveries of the past decade and indicate areas that have yet to be resolved. While significant progress regarding their chemistry and pharmacology has been made since the 1960s, it is clear that the iboga alkaloids will continue to stoke scientific innovation for years to come.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 32794540      PMCID: PMC7882011          DOI: 10.1039/d0np00033g

Source DB:  PubMed          Journal:  Nat Prod Rep        ISSN: 0265-0568            Impact factor:   13.423


  128 in total

Review 1.  Medicinal chemistry of hERG optimizations: Highlights and hang-ups.

Authors:  Craig Jamieson; Elizabeth M Moir; Zoran Rankovic; Grant Wishart
Journal:  J Med Chem       Date:  2006-08-24       Impact factor: 7.446

2.  Tissue distribution of ibogaine after intraperitoneal and subcutaneous administration.

Authors:  L B Hough; S M Pearl; S D Glick
Journal:  Life Sci       Date:  1996       Impact factor: 5.037

3.  Structurally modified ibogaine analogs exhibit differing affinities for NMDA receptors.

Authors:  R T Layer; P Skolnick; C M Bertha; U K Bandarage; M E Kuehne; P Popik
Journal:  Eur J Pharmacol       Date:  1996-08-08       Impact factor: 4.432

4.  Selectivity of coronaridine congeners at nicotinic acetylcholine receptors and inhibitory activity on mouse medial habenula.

Authors:  Hugo R Arias; Xiaotao Jin; Dominik Feuerbach; Ryan M Drenan
Journal:  Int J Biochem Cell Biol       Date:  2017-10-16       Impact factor: 5.085

5.  Extraction and Conversion Studies of the Antiaddictive Alkaloids Coronaridine, Ibogamine, Voacangine, and Ibogaine from Two Mexican Tabernaemontana Species (Apocynaceae).

Authors:  Felix Krengel; Marco V Mijangos; Marisol Reyes-Lezama; Ricardo Reyes-Chilpa
Journal:  Chem Biodivers       Date:  2019-06-13       Impact factor: 2.408

Review 6.  Function-oriented synthesis, step economy, and drug design.

Authors:  Paul A Wender; Vishal A Verma; Thomas J Paxton; Thomas H Pillow
Journal:  Acc Chem Res       Date:  2007-12-27       Impact factor: 22.384

7.  Biogenetically inspired synthesis and skeletal diversification of indole alkaloids.

Authors:  Haruki Mizoguchi; Hideaki Oikawa; Hiroki Oguri
Journal:  Nat Chem       Date:  2013-11-24       Impact factor: 24.427

8.  Noribogaine reduces nicotine self-administration in rats.

Authors:  Qing Chang; Taleen Hanania; Deborah C Mash; Emeline L Maillet
Journal:  J Psychopharmacol       Date:  2015-05-20       Impact factor: 4.153

9.  Psychoplastogens: A Promising Class of Plasticity-Promoting Neurotherapeutics.

Authors:  David E Olson
Journal:  J Exp Neurosci       Date:  2018-09-19

10.  Mechanism of hERG channel block by the psychoactive indole alkaloid ibogaine.

Authors:  Patrick Thurner; Anna Stary-Weinzinger; Hend Gafar; Vaibhavkumar S Gawali; Oliver Kudlacek; Juergen Zezula; Karlheinz Hilber; Stefan Boehm; Walter Sandtner; Xaver Koenig
Journal:  J Pharmacol Exp Ther       Date:  2013-12-04       Impact factor: 4.402

View more
  9 in total

1.  Psychedelics re-engineered for potential use in the clinic.

Authors:  Gabriela Manzano-Nieves; Conor Liston
Journal:  Nature       Date:  2021-01       Impact factor: 49.962

2.  Synthesis of Tertiary Amines through Extrusive Alkylation of Carbamates.

Authors:  Guoliang Zhang; David Favela; Winston L Chow; Rishab N Iyer; Alexander J Pell; David E Olson
Journal:  Org Lett       Date:  2022-08-16       Impact factor: 6.072

Review 3.  Psychedelic-inspired approaches for treating neurodegenerative disorders.

Authors:  Hannah N Saeger; David E Olson
Journal:  J Neurochem       Date:  2021-12-05       Impact factor: 5.546

4.  The Promise of Psychedelic Science.

Authors:  David E Olson
Journal:  ACS Pharmacol Transl Sci       Date:  2021-03-25

Review 5.  Overcoming Depression with 5-HT2A Receptor Ligands.

Authors:  Agata Zięba; Piotr Stępnicki; Dariusz Matosiuk; Agnieszka A Kaczor
Journal:  Int J Mol Sci       Date:  2021-12-21       Impact factor: 5.923

6.  Iboga Inspired N-Indolylethyl-Substituted Isoquinuclidines as a Bioactive Scaffold: Chemoenzymatic Synthesis and Characterization as GDNF Releasers and Antitrypanosoma Agents.

Authors:  Mariana Pazos; Estefania Dibello; Juan Manuel Mesa; Dalibor Sames; Marcelo Alberto Comini; Gustavo Seoane; Ignacio Carrera
Journal:  Molecules       Date:  2022-01-27       Impact factor: 4.411

Review 7.  Recent Advances in Divergent Synthetic Strategies for Indole-Based Natural Product Libraries.

Authors:  Taegwan Kim; Min Woo Ha; Jonghoon Kim
Journal:  Molecules       Date:  2022-03-27       Impact factor: 4.411

8.  Efficient Access to the Iboga Skeleton: Optimized Procedure to Obtain Voacangine from Voacanga africana Root Bark.

Authors:  Bruno González; Catherine Fagúndez; Alejandro Peixoto de Abreu Lima; Leopoldo Suescun; Diver Sellanes; Gustavo A Seoane; Ignacio Carrera
Journal:  ACS Omega       Date:  2021-06-24

9.  Engineering Safer Psychedelics for Treating Addiction.

Authors:  Jamie Peters; David E Olson
Journal:  Neurosci Insights       Date:  2021-07-20
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.